Amir Fathi, MD, Massachusetts General Hospital

home / authors / amir-fathi,-md,-massachusetts-general-hospital

Articles

Optimizing Treatment Selection for Patients with FLT3-ITD AML

Optimizing Treatment Selection for Patients with FLT3-ITD AML

Naval G. Daver, MD;Amir Fathi, MD, Massachusetts General Hospital;Margaret T. Kasner, MD;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
July 24th 2023

Discussion centered around optimal strategies to effectively treat, and improve outcomes for, patients with FLT3-ITD AML.

Read More

Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML

Standard Approach to Treatment for Fit Patients with Newly Diagnosed AML

Naval G. Daver, MD;Amir Fathi, MD, Massachusetts General Hospital;Margaret T. Kasner, MD;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
July 17th 2023

Recommendations for community oncologists concerning the treatment of fit patients diagnosed with AML.

Read More

Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia

Clinical Insights Concerning Molecular Testing in Patients Diagnosed with Acute Myeloid Leukemia

Naval G. Daver, MD;Amir Fathi, MD, Massachusetts General Hospital;Margaret T. Kasner, MD;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
July 17th 2023

Eunice S. Wang, MD opens a discussion with other panelists concerning the benefits of germline testing in AML, NCCN guidelines for molecular testing, and how molecular testing in AML is advancing over time.

Read More

Expert on AML

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

Amir Fathi, MD, Massachusetts General Hospital
July 12th 2023

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

Read More

An Introduction to Biomarker Testing in Acute Myeloid Leukemia

An Introduction to Biomarker Testing in Acute Myeloid Leukemia

Naval G. Daver, MD;Amir Fathi, MD, Massachusetts General Hospital;Margaret T. Kasner, MD;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
June 26th 2023

Experienced clinicians highlight the role of biomarker testing in AML for optimal patient care and treatment selection.

Read More

An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia

An Overview of Incidence, Diagnosis, and Subtype Classification in Acute Myeloid Leukemia

Naval G. Daver, MD;Amir Fathi, MD, Massachusetts General Hospital;Margaret T. Kasner, MD;Eunice Wang, MD, Roswell Park Comprehensive Cancer Center
June 26th 2023

Moderator Naval G. Daver, MD introduces expert panelists and leads an overview of Acute Myeloid Leukemia, focusing on the importance of timely diagnosis and risk assessment for patients with AML.

Read More

Progress in the Treatment of AML

Progress in the Treatment of AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Implications for Treating AML With CC-486

Implications for Treating AML With CC-486

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

CC-486 Maintenance Therapy in AML

CC-486 Maintenance Therapy in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Gemtuzumab for AML

Gemtuzumab for AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

CPX-351 in Newly Diagnosed Secondary AML

CPX-351 in Newly Diagnosed Secondary AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Differentiation Syndrome and IDH Inhibitors in AML

Differentiation Syndrome and IDH Inhibitors in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

IDH Inhibitors and MDS

IDH Inhibitors and MDS

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

IDH1/2 Inhibitors for AML

IDH1/2 Inhibitors for AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

IDH Mutations in AML

IDH Mutations in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

FLT3 Triplet Regimens for AML

FLT3 Triplet Regimens for AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Monitoring Response to Venetoclax Regimens in AML

Monitoring Response to Venetoclax Regimens in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Venetoclax in AML: Safety Profile

Venetoclax in AML: Safety Profile

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Optimal Use of Venetoclax in AML

Optimal Use of Venetoclax in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

VIALE Studies in AML

VIALE Studies in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Utilization of Second-Generation FLT3 Inhibitors in AML

Utilization of Second-Generation FLT3 Inhibitors in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Second-Generation FLT3 Inhibitors in AML

Second-Generation FLT3 Inhibitors in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

FLT3-Mutated AML: Midostaurin and Chemotherapy

FLT3-Mutated AML: Midostaurin and Chemotherapy

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

FLT3 Genetic Alterations in AML

FLT3 Genetic Alterations in AML

Harry P. Erba, MD, PhD, Duke University School of Medicine;Amir Fathi, MD, Massachusetts General Hospital;Mark J. Levis, MD, PhD, Johns Hopkins University;Gail J. Roboz, MD, Weill Cornell Medical Center;Daniel Pollyea, MD, MS, University of Colorado Denver
July 20th 2020

Read More

Latest Updated Articles

Alexis LeVee, MD
Published: May 14th 2025 | Updated: May 30th 2025
Breast Cancer Experts Bookmark Top Abstracts to Watch at the 2025 ASCO Annual Meeting
Arielle Heeke, MD
Published: May 2nd 2025 | Updated: May 6th 2025
Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Published: March 10th 2025 | Updated: April 25th 2025
Bridging Data and Expert Insights: Paving the Way for Improved CLL Outcomes
Núria Agustí Garcia, MD
Published: April 21st 2025 | Updated: April 23rd 2025
Dr Agustí on Patient Eligibility for Evaluating Chemoradiotherapy vs Radiotherapy Alone in Intermediate-Risk Cervical Cancer
Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Published: April 16th 2025 | Updated: April 18th 2025
Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer
Published: February 18th 2025 | Updated: April 17th 2025
Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer